OncoMatch/Clinical Trials/NCT06934057

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Is NCT06934057 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Nivolumab and Cabozantinib for kidney cancer.

Phase 4RecruitingGustave Roussy, Cancer Campus, Grand ParisNCT06934057Data as of Jun 2026Location: France

Treatment: Nivolumab · Cabozantinib — The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Nivolumab

Targeted therapy

Cabozantinib

Cancer type

Renal Cell Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≥ 70

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06934057 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Renal Cell Carcinoma trials